Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up

Hanne Ø Larsen; Anne S Roug; Tom Just; Gordon D Brown; Peter Hokland

doi:10.1002/cyto.b.20614

Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up

Hanne Ø Larsen
, Anne S Roug
, Tom Just
, Gordon D Brown
, Peter Hokland

Applied Medicine

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

Abstract

Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.

Original language	English
Pages (from-to)	3-8
Number of pages	6
Journal	Cytometry Part B: Clinical Cytometry
Volume	82B
Issue number	1
Early online date	30 Aug 2011
DOIs	https://doi.org/10.1002/cyto.b.20614
Publication status	Published - Jan 2012

Keywords

AML
hMICL
immunophenotyping
LAIP
MRD

Access to Document

10.1002/cyto.b.20614

Cite this

@article{57a7d01c17a745f388668760974da5e5,

title = "Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up",

abstract = "Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.",

keywords = "AML, hMICL, immunophenotyping, LAIP, MRD",

author = "Larsen, \{Hanne {\O}\} and Roug, \{Anne S\} and Tom Just and Brown, \{Gordon D\} and Peter Hokland",

note = "Copyright {\textcopyright} 2011 International Clinical Cytometry Society.",

year = "2012",

month = jan,

doi = "10.1002/cyto.b.20614",

language = "English",

volume = "82B",

pages = "3--8",

journal = "Cytometry Part B: Clinical Cytometry",

issn = "1552-4957",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Expression of the hMICL in acute myeloid leukemia

T2 - a highly reliable disease marker at diagnosis and during follow-up

AU - Larsen, Hanne Ø

AU - Roug, Anne S

AU - Just, Tom

AU - Brown, Gordon D

AU - Hokland, Peter

PY - 2012/1

Y1 - 2012/1

N2 - Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.

AB - Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.

KW - AML

KW - hMICL

KW - immunophenotyping

KW - LAIP

KW - MRD

U2 - 10.1002/cyto.b.20614

DO - 10.1002/cyto.b.20614

M3 - Article

C2 - 22173921

SN - 1552-4957

VL - 82B

SP - 3

EP - 8

JO - Cytometry Part B: Clinical Cytometry

JF - Cytometry Part B: Clinical Cytometry

IS - 1

ER -

Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up

Abstract

Keywords

Access to Document

Fingerprint

Cite this